enGene Holdings Inc. — Director's Dealing 2025

Jun 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: enGene Holdings Inc. (ENGN)
CIK: 0001980845
Period of Report: 2025-06-16

Reporting Person: BRUNK GERALD A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-16	Stock Option (Right to Buy)	$3.31	A	22500	Acquired	2035-06-16	Common Shares (22500)	Direct

Footnotes

F1: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders.

F2: These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk expressly disclaims beneficial ownership of these securities.